We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.
Life Sciences and Health Care frame

Life Sciences and Health Care

Navigating complexities in the life sciences and health care industries is no easy task. Successfully competing in the space requires a partner with a holistic, collaborative approach and a global perspective. It calls for a strategy informed by asking the right questions and rooted in identifying creative solutions to your unique challenges.

For life sciences innovators of all sizes, anywhere in the world, Hogan Lovells is that partner — from cutting-edge start-ups and boutique venture funds to world-renowned research institutions and health systems to global biopharmaceutical conglomerates.

Your business and your challenges don’t stop for oceans or disappear at national borders. Neither does Hogan Lovells. Our team of 500 life sciences and health care lawyers is located around the world but operates as if everyone is working from the same office — providing a seamless experience everywhere you do business.

And no matter the challenge — from creation to commercialization of a life-saving therapy, regulatory compliance to an international patent dispute, the formation of a strategic alliance to a complex, global merger — we’ve been there before and we understand how to prepare you for what happens next, helping you to anticipate risks and address future issues before they arise.

Whatever your challenge, wherever the issue, Hogan Lovells has you covered. It’s that easy.

Digital Health Guide

In this guide, our Global Digital Health Team provides strategic guidance for leveraging digital health opportunities in 2018.

Expanding access to unapproved treatments through right-to-try

State-level right-to-try laws have paved the way for a new law at the federal level. Robert Church discusses the risks and opportunities for patients and the biopharmaceutical industry.

Government data mining leads to more aggressive investigations

Partners Maria Durant and Gejaa Gobena discuss how the U.S. government’s increasing ability to analyze Medicare and Medicaid data is changing the role of large-scale data analysis in...

Why digital tools are critical to life sciences players

Partner Dr. Jörg Schickert says digital health tools are becoming a permanent part of the healthcare landscape, and a way forward for life sciences companies.

Generic Drugs Taking Hold in the Asian Marketplace

Dr. Frederick Ch’en explains the practical impact on pharmaceutical companies doing business in the region.

Building a Sound Strategy Against False Advertising Claims in Europe

Tanja Eisenblätter discusses five key points for manufacturers operating in Europe when considering false advertising claims.

Foreign Device Manufacturers May Face Increased FDA Inspections

Mike Heyl says that foreign device manufacturers should anticipate greater chance of inspection under new U.S. FDA leadership.

Representative experience

Representing TESARO in its US$101m Series B financing, its IPO, and all of its follow-on equity financings and US$165m notes financing.

Advising a leading pharma company on its innovative approach regarding digital health offerings.

Global defense of TÜV Rheinland against liability claims resulting from allegedly inappropriate certification of breast implant manufacturer P.I.P.

Advising a drug company on strategies for obtaining orphan drug approval and working with scientific and regulatory groups to draft and submit designation request.

Advising a U.S. medical device company on regulatory and commercial issues regarding the market launch of a gene test in 24 European countries.

Advising MorphoSys AG in a worldwide license and collaboration agreement with Emergent Biosolutions to develop an antibody for the treatment of prostate cancer.

Handling hospital transactions for the University of Minnesota, Saint Louis University, Georgetown University, the University of Miami, the State University of New York, and more.

Instrumental in persuading FDA to change longstanding regulatory position on awarding exclusivity to fixed-dose combination products, benefitting Gilead’s products in the HIV and Hepatitis C fields.

Lead agency counsel for implementation of Affordable Care Act, including provisions governing health insurance coverage and Medicare Advantage plans.

Obtained a permanent injunction for a leading Japanese pharmaceutical firm in a bench trial on infringement and validity.

Representation of a global technology company in the creation of a joint venture to develop next-generation surgical robots.

Representing Allergan in the acquisition of rights to Ironwood Pharmaceuticals’ linaclotide product (CONSTELLA®) in more than 40 countries outside the U.S.

Representing Anthem, Inc. in more than 100 class action lawsuits that have been filed around the country related to their cyberattack. 

Representing Novartis in an exclusive global collaboration agreement with the University of Pennsylvania to develop and commercialize immunotherapies for cancer.

Representing Novartis in its landmark portfolio transformation transactions with GlaxoSmithKline and Eli Lilly valued at more than US$23bn.

Representing pharmaceutical and biologics companies in connection with numerous federal and state investigations of sales and marketing, pricing, Medicaid rebate, FDCA promotional issues, and cGMP compliance.

Representing provider networks in multiple investigations of their clinical integration and joint negotiations with health plans by federal and/or state antitrust enforcers.

Advising Lilly in its European patent disputes concerning its oncology product, pemetrexed.


Ranked Band 1 for Life Sciences

Chambers Global


Ranked Band 1 for Life Sciences Europe-wide

Chambers Europe


Ranked Band 1 for Life Sciences in Italy

Chambers Europe


Ranked Band 1 for Life Sciences in Belgium

Chambers Europe


Ranked Band 1 for Life Sciences in The Netherlands

Chambers Europe


Ranked Band 1 for Healthcare - District of Columbia

Chambers USA


Ranked Band 1

JUVE Handbook


Ranked Band 1 for EU Regulatory: Pharmaceuticals, Medical Devices, and Biotech in Belgium

The Legal 500


Ranked Band 1 for Healthcare and Life Sciences in The Netherlands

The Legal 500


Ranked Band 1 for Healthcare and Life Sciences in Germany

The Legal 500


Ranked Band 1 for Healthcare and Life Sciences in France

The Legal 500


Ranked Band 1 for Healthcare and Life Sciences in Italy

The Legal 500


Healthcare Team of the Year

Chambers USA


Life Cycle Firm with 28 Life Sciences Stars 2016

LMG Life Sciences


Leading law firm for Life Sciences with 40 individual listings

Who's Who Legal Life Sciences


Awarded "Law Firm of the Year" for Pharmaceuticals Law in Germany


Latest thinking and events

Loading data